Public Company News
China Literature Limited Announces Changes to its Management Team
Appoints Mr. Hou Xiaonan as Chief Executive Officer HONG KONG, May 9, 2023 /PRNewswire/ -- China Literature Limited ("China Literature" or "the Company", stock code: 0772), a leading online literature and intellectual property ("IP") incubation platform inChina, today announced that Mr. Cheng Wu...
2023-05-09 17:16
3098
Aker Horizons and VNG sign letter of intent to supply green ammonia from Norway to Germany
FORNEBU, Norway, May 9, 2023 /PRNewswire/ -- Aker Horizons ASA (OSE: AKH), a developer of green energy and industry, has signed a letter of intent (LOI) with the German gas group VNG to supply green ammonia from Narvik,Northern Norway. VNG intends to procure up to 200,000 tonnes of green ammonia...
2023-05-09 16:22
1945
The 2023 Bund Art Festival is Coming, Starting a One-stop Art Tour at the Great Yu Garden Area
HONG KONG, May 9, 2023 /PRNewswire/ -- Experience the charm of diverse art collisions on the Bund this summer! FromMay 6th to May 31st, 2023, the third edition of Bund Art Festival is launched on the bundShanghai, jointly created by the Fosun Foundation, Bund Financial Center (BFC) and Yu Yuan Ga...
2023-05-09 14:54
2712
Artmarket.com: Artprice to introduce its own AI for the art market - Intuitive Artmarket®
PARIS, May 9, 2023 /PRNewswire/ -- Artprice by Artmarket's deployment of algorithmic AI via its proprietary Intuitive Artmarket® is a tool that can generate highly relevant and personalized recommendations, allowing users to go infinitely further in their discovery of art and the art market. Ser...
2023-05-09 13:00
2893
3 in 5 people Have Side Job to Help Make Ends Meet - Herbalife Asia Pacific Survey
SINGAPORE, May 9, 2023 /PRNewswire/ -- Herbalife, a global health and wellness company and community, released the findings of its 2023 Asia Pacific Side Job Survey which showed that almost 3 in 5 (59%) respondents have a side job, and the top reason for doing so is to make ends meet (61%). Other...
2023-05-09 12:22
966
IND Application for Phase Ⅲ Registration Study of KN026 in Combination with Chemotherapy for the First-line Treatment of Breast Cancer Was Approved by CDE
SUZHOU, China, May 9, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. jointly announced that the IND application was approved in China for the pivotal trial of the anti-HER2 bispecific antibody KN026 combined with Docetaxel (albumin-binding), i...
2023-05-09 10:00
2545
Eye Level Launches New Visual Communication Design to Celebrate Its 11th Anniversary of Rebranding
SEOUL, South Korea, May 9, 2023 /PRNewswire/ -- Eye Level, a leading educational institution that provides personalized learning for children, has launched a new visual communication design to commemorate its 11th anniversary of rebranding. The institution's new design reflects the evolution of i...
2023-05-09 08:24
2297
Amcor announces intent to acquire Moda Systems
Will provide Amcor with fully integrated, production-ready fresh protein packaging solution ZURICH, May 9, 2023 /PRNewswire/ -- Amcor (NYSE: AMCR; ASX: AMC), a global leader in developing and producing responsible packaging solutions, today announced that it has signed a definitive agreement to ...
2023-05-09 04:30
3568
Tuya Smart Enters Strategic Partnership With T3 Technology and Skyworth Digital to Build a Global Smart Home Ecosystem
SHENZHEN, China, May 8, 2023 /PRNewswire/ -- Tuya Smart (NYSE: TUYA, HKEX: 2391), a global IoT development platform service provider, today entered a trilateral strategic partnership with T3 Technology, a prominent telecom solutions provider inSoutheast Asia, and Skyworth Digital, a digital home ...
2023-05-08 21:57
3921
GWM Holds All NEV Experience Event to Display Its New Energy Strategy
BAODING, China, May 8, 2023 /PRNewswire/ -- Recently, GWM held a global media experience event on its new energy products in Baoding,China. The event demonstrated its commitment to electrification as well as its brand value of "Go With More" with series of new energy intelligent products to be la...
2023-05-08 20:13
4496
Pixelworks Visual Display Technology Brings Smooth 120fps Mobile Gaming Experience to "Crystal of Atlan"
Optimizes the Visual Quality of Mobile Games, from Production to Display; Presents the Authentic 'Atlan World' Where Magic and Machinery Play Together on Smartphones SHANGHAI, May 8, 2023 /PRNewswire/ -- Pixelworks, Inc. (NASDAQ: PXLW), a leading provider of visual processing solutions, today an...
2023-05-08 18:00
3349
XCMG Machinery's 2022 Annual Report Highlights Resilience and Technological Innovation Post-Pandemic
XUZHOU, China, May 8, 2023 /PRNewswire/ -- XCMG Machinery ("XCMG", SHE:000425), a global leader in construction machinery, recently published its 2022 Annual Report, showing strong performance with total revenue of93.817 billion yuan and net profit attributable to shareholders of4.307 billion yua...
2023-05-08 16:58
2862
Ascletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus Infection
--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection --Preclinical research showed that ...
2023-05-08 16:50
2794
Transcenta to Present Two Clinical Trial Progress at ASCO 2023
SUZHOU, China, May 8, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that two posters for c...
2023-05-08 14:55
2280
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
TAIPEI, May 8, 2023 /PRNewswire/ -- EirGenix, Inc. (6589.TT) announced on 28th of April that it has completed the phase 1 clinical trial (EGC101) of its second breast cancer biosimilar EG1206A inEurope. Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show th...
2023-05-08 10:00
2258
Eye Level Launches New Visual Communication Design to Celebrate Its 11th Anniversary of Rebranding
SEOUL, South Korea, May 8, 2023 /PRNewswire/ -- Eye Level, a leading educational institution that provides personalized learning for children, has launched a new visual communication design to commemorate its 11th anniversary of rebranding. The institution's new design reflects the evolution of i...
2023-05-08 09:49
2074
Eye Level Launches New Visual Communication Design to Celebrate Its 11th Anniversary of Rebranding
SEOUL, South Korea, May 8, 2023 /PRNewswire/ -- Eye Level, a leading educational institution that provides personalized learning for children, has launched a new visual communication design to commemorate its 11th anniversary of rebranding. The institution's new design reflects the evolution of i...
2023-05-08 09:02
2297
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine
ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-08 08:00
4122
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
ROCKVILLE, MD. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2023-05-08 08:00
3484
Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites
MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injectio...
2023-05-08 05:00
2469
Week's Top Stories
Most Reposted
ROSHI Unveils Comprehensive Report on the Future of Digital Lending, Highlighting Global Trends for 2025 and Beyond
[Picked up by 317 media titles]
2024-10-02 10:03
Matterport Fall 2024 Release: Insights Meets Imagination elevates the platform with generative AI and more
[Picked up by 305 media titles]
2024-10-02 09:00
From Boomers to Zoomers: how retailers and eCommerce firms can boost sales and loyalty
[Picked up by 305 media titles]
2024-09-30 13:00
Graid Technology and INFINITIX Turn Your SuperPOD into a Real Business Opportunity at Tech Week Singapore
[Picked up by 293 media titles]
2024-10-04 11:00
MOAJ Holding invests $30M in Joint Venture with MediSun Energy to Tackle Water Scarcity and Brine Challenges in Saudi Arabia
[Picked up by 293 media titles]
2024-09-30 09:00
Most Read
Matterport Fall 2024 Release: Insights Meets Imagination elevates the platform with generative AI and more
2024-10-02 09:00
10537
ROSHI Unveils Comprehensive Report on the Future of Digital Lending, Highlighting Global Trends for 2025 and Beyond
2024-10-02 10:03
9906
From Boomers to Zoomers: how retailers and eCommerce firms can boost sales and loyalty
2024-09-30 13:00
7024